Neoplasms in IMIDs: a review of the literature
Immune-mediated inflammatory diseases (IMIDs) are chronic and disabling diseases that share common inflammatory and immunological dysregulation. The association between IMIDs and the risk of cancer remains debatable. Inflammation is a double-edged sword for cancer as it can help destroy malignant ce...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publicaciones Permanyer
2022-10-01
|
| Series: | Journal of IMIDs |
| Subjects: | |
| Online Access: | https://www.journalofimids.com/frame_esp.php?id=25 |
| _version_ | 1797829141284782080 |
|---|---|
| author | Jon Fulgencio-Barbarin Mario Puerta-Peña Daniel Falkenhain-Lopez Carmen Garcia-Donoso Raquel Rivera Diaz |
| author_facet | Jon Fulgencio-Barbarin Mario Puerta-Peña Daniel Falkenhain-Lopez Carmen Garcia-Donoso Raquel Rivera Diaz |
| author_sort | Jon Fulgencio-Barbarin |
| collection | DOAJ |
| description | Immune-mediated inflammatory diseases (IMIDs) are chronic and disabling diseases that share common inflammatory and immunological dysregulation. The association between IMIDs and the risk of cancer remains debatable. Inflammation is a double-edged sword for cancer as it can help destroy malignant cells but it can also promote the development of some cancers. The following review aims to provide a summary of the associations of neoplasms and the most common IMIDs and the possible relationship of the indirect risk caused by their chronic therapy. The risk of developing neoplasm is higher globally in patients with IMID, with different risk profiles and tumor types depending on the inflammatory pathology. Overall, lymphoproliferative disorders are the most common cancer in IMID patients. Nowadays, data available on the safety of the drugs used in IMID patients showed no increased risk of neoplasms in general, although more studies are needed.
|
| first_indexed | 2024-04-09T13:15:41Z |
| format | Article |
| id | doaj.art-7ab1417232dc4c4ea3fd50abbcbbc635 |
| institution | Directory Open Access Journal |
| issn | 2696-824X |
| language | English |
| last_indexed | 2024-04-09T13:15:41Z |
| publishDate | 2022-10-01 |
| publisher | Publicaciones Permanyer |
| record_format | Article |
| series | Journal of IMIDs |
| spelling | doaj.art-7ab1417232dc4c4ea3fd50abbcbbc6352023-05-11T22:27:41ZengPublicaciones PermanyerJournal of IMIDs2696-824X2022-10-012410.24875/JIMIDS.22000002Neoplasms in IMIDs: a review of the literatureJon Fulgencio-Barbarin0Mario Puerta-Peña1Daniel Falkenhain-Lopez2Carmen Garcia-Donoso3Raquel Rivera Diaz4Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, SpainDepartment of Dermatology, Hospital Universitario 12 de Octubre, Madrid, SpainDepartment of Dermatology, Hospital Universitario 12 de Octubre, Madrid, SpainDepartment of Dermatology, Hospital Universitario 12 de Octubre, Madrid, SpainDepartment of Dermatology, Hospital Universitario 12 de Octubre, Madrid, SpainImmune-mediated inflammatory diseases (IMIDs) are chronic and disabling diseases that share common inflammatory and immunological dysregulation. The association between IMIDs and the risk of cancer remains debatable. Inflammation is a double-edged sword for cancer as it can help destroy malignant cells but it can also promote the development of some cancers. The following review aims to provide a summary of the associations of neoplasms and the most common IMIDs and the possible relationship of the indirect risk caused by their chronic therapy. The risk of developing neoplasm is higher globally in patients with IMID, with different risk profiles and tumor types depending on the inflammatory pathology. Overall, lymphoproliferative disorders are the most common cancer in IMID patients. Nowadays, data available on the safety of the drugs used in IMID patients showed no increased risk of neoplasms in general, although more studies are needed. https://www.journalofimids.com/frame_esp.php?id=25Immune-mediated inflammatory disease. Neoplasms. Cancer. Tumor. Inflammation. |
| spellingShingle | Jon Fulgencio-Barbarin Mario Puerta-Peña Daniel Falkenhain-Lopez Carmen Garcia-Donoso Raquel Rivera Diaz Neoplasms in IMIDs: a review of the literature Journal of IMIDs Immune-mediated inflammatory disease. Neoplasms. Cancer. Tumor. Inflammation. |
| title | Neoplasms in IMIDs: a review of the literature |
| title_full | Neoplasms in IMIDs: a review of the literature |
| title_fullStr | Neoplasms in IMIDs: a review of the literature |
| title_full_unstemmed | Neoplasms in IMIDs: a review of the literature |
| title_short | Neoplasms in IMIDs: a review of the literature |
| title_sort | neoplasms in imids a review of the literature |
| topic | Immune-mediated inflammatory disease. Neoplasms. Cancer. Tumor. Inflammation. |
| url | https://www.journalofimids.com/frame_esp.php?id=25 |
| work_keys_str_mv | AT jonfulgenciobarbarin neoplasmsinimidsareviewoftheliterature AT mariopuertapena neoplasmsinimidsareviewoftheliterature AT danielfalkenhainlopez neoplasmsinimidsareviewoftheliterature AT carmengarciadonoso neoplasmsinimidsareviewoftheliterature AT raquelriveradiaz neoplasmsinimidsareviewoftheliterature |